Enoyl-acyl carrier protein reductase (ENR) catalyzes the last reduction step in the bacterial type II fatty acid biosynthesis cycle. ENRs include FabI, FabL, FabL2, FabK, and FabV. Previously, we reported a unique triclosan (TCL) resistant ENR homolog that was predominant in obligate ...
英文别名: enoyl-(acyl-carrier-protein)reductase (NADPH)中文名: 中文别名: CBNumber: CB01359121 分子式: 分子量: 0 MOL File: Mol file 化学性质 安全信息 用途 供应商 2 enoyl-(acyl-carrier-protein)reductase (NADPH)化学性质 安全信息enoyl-(acyl-carrier-protein)reductase (NADPH)性质、用途与生产工艺...
ChemicalBook 致力于为化学行业用户提供enoyl-(acyl-carrier-protein) reductase (NADH)的性质、化学式、分子式、比重、密度,同时也包括enoyl-(acyl-carrier-protein) reductase (NADH)的沸点、熔点、MSDS、用途、作用、毒性、价格、生产厂家、用途、上游原料、下游产品等信
Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB IProkayrotic FAB I polypeptides and DNA (RNA) encoding such FAB I and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FAB I ...
Preparations of NADH-specific and NADPH-specific, 3-oxoacyl-[acyl-carrier-protein] reductase enzymes (EC 1.1.1.100), enoyl-[acyl-carrier-protein] reductase... I Caughey,RGO Kekwick - 《European Journal of Biochemistry》 被引量: 120发表: 1982年 Discovery of a Novel and Potent Class of F. ...
Enoylacyl carrier protein reductase (also called ENR or FabI and a product of the fabI gene) is an enzyme required in a critical step of bacterial fatty acid biosynthesis and has attracted attention as a target of novel antimicrobial agents. We determined the crystal structures of FabI from Ca...
1. AFN-1252: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI inhibitor Antibacterial agent [J] . GrasJ. Drugs of the Future . 2014,第7期 机译:AFN-1252:壬酰基-[酰基载体蛋白]还原酶[NADH] FabI抑制剂抗菌剂 2. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning...
Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. OBJECTIVES: This study was performed to analyse in vitro and in vivo activities of CG400549, a new FabI inhibitor, against clinical isolates of staphylococ... Park HSYoon YMJung SJ...
The present invention relates to polypeptide targets for pathogenic bacteria, especially enoyl-(acyl-carrier-protein) reductase (FabK) from Staphylococcus pneumoniae. The invention provides purified, soluble forms of FabK polypeptide suitable for structural and functional characterization by mass spectrometry...
Article: CDNA cloning and expression of Brassica napus enoyl-acyl carrier protein reductase in Escherichia coli